Overview
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALN-TTRSC04 in Healthy Subjects
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-06-01
2025-06-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single ascending doses of ALN-TTRSC04.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Alnylam Pharmaceuticals
Criteria
Inclusion Criteria:- Body mass index (BMI) ≥18.0 kg/m^2 and ≤30 kg/m^2 assessed at Screening.
Exclusion Criteria:
- Has an estimated glomerular filtration rate (eGFR) <90 mL/min/1.73m^2 at screening.
- Has alanine aminotransferase (ALT), aspartate aminotransferase (AST) or direct
bilirubin above the upper limit of normal (ULN).